President Joe Biden likely has BA.5 variant but Covid-19 symptoms ‘continue to improve,’ doctor says

President Joe Biden likely has BA.5 variant but Covid-19 symptoms ‘continue to improve,’ doctor says


President Joe Biden, who tested positive today for Covid-19 this morning, posts on Twitter “Folks, I’m doing great. Thanks for your concern. Just called Senator Casey, Congressman Cartwright, and Mayor Cognetti (and my Scranton cousins!) to send my regrets for missing our event today.”

Courtesy: White House

President Joe Biden likely has the BA.5 Covid-19 variant but his symptoms “continue to improve,” according to the White House.

“His primary symptoms, though less troublesome, now include sore throat, rhinorrhea, loose cough and body aches,” White House physician Kevin O’Connor said in a memorandum on Saturday.

The president on Friday completed his second full day of Pfizer’s Paxlovid, an antiviral pill that can reduce the risk of hospitalization for Covid-19 patients, O’Connor said.

While the president is responding to the therapy “as expected,” he has likely contracted the Covid-19 BA.5 variant, which is currently responsible for 70% to 85% of U.S. infections.

Biden, who is fully vaccinated and received two booster shots, tested positive for Covid-19 on Thursday and has reported “very mild symptoms.”



Source

Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera
Health

Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, with both pharmaceutical giants raising their bids for the startup as of Monday.  […]

Read More
Pfizer tops estimates, raises profit guidance even as sales fall
Health

Pfizer tops estimates, raises profit guidance even as sales fall

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]

Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Health

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]

Read More